-IPS News Dr. Babatunde Osotimehin is the Executive Director of UNFPA, the United Nations Population Fund UNITED NATIONS: The tragic deaths and injuries of women following sterilisation in the Indian state of Chhattisgarh have sparked global media coverage and public concern and outrage. Now we must ensure that such a tragedy never occurs again. The women underwent surgery went with the best intentions - hoping they were doing the right thing for themselves and...
More »SEARCH RESULT
Total Matching Records found : 345
Billing for wallet shock -Digbijay Mishra
-Business Standard Indian and other generic drug firms face prospect of US legislature debating compensation for undue price rises Indian generic drug makers might, if a proposed US law comes about, need to pay a rebate to the federal Medicaid programme there when prices of their medications outpace inflation. A Bill is to be introduced in the US Senate by a member, aimed to cushion the impact on taxpayers in this manner...
More »Access denied -Kundan Pandey
-Down to Earth Shortage of antiretroviral drugs and lack of diagnosis is not new in India, but government does not admit to the crisis The fight against HIV/AIDS in India is becoming tougher by the day as patients continue to face an acute shortage of antiretroviral drugs. This is an alarming situation for a country with the third-highest number of HIV+ people in the world-2.1 million. In 2012, about 140,000 people in...
More »A reality check on intellectual property concerns -Moushami Joshi and Srividhya Ragavan
-The Hindu The Working Group on Intellectual Property can serve as a platform where real time solutions to meet India's need for low-cost medicines can be addressed After what seemed like a historic trip for Prime Minister Narendra Modi, which held out the promise of reshaping India-U.S. relations positively, the initiation of the Out-of-Cycle Review (OCR) by the United States Trade Representative (USTR) has brought a sobering reality check as to what...
More »New hepatitis drug to cost more in middle income nations; activists cry foul -Jyotsna Singh
-Down to Earth Pharma company's strategy of different prices for different countries to affect quality treatment of 185 million people infected with Hepatitis C worldwide Health activists and agencies on Tuesday criticised leading pharmaceutical company Bristol-Myers Squibb (BMS)'s commercial strategy to sell new Hepatitis C medicine Daclatasvir, stating it would exclude a large number of patients who cannot afford expensive treatment. BMS had announced that it would create a tiered pricing strategy for...
More »
